Nano Cap New Millennium Growth Fund L P Invests $743,000 in IDEAYA Biosciences, Inc. $IDYA

Nano Cap New Millennium Growth Fund L P purchased a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,500 shares of the company’s stock, valued at approximately $743,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in IDEAYA Biosciences by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock valued at $173,518,000 after buying an additional 97,116 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of IDEAYA Biosciences by 54.6% in the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after buying an additional 1,156,716 shares during the period. Fiera Capital Corp lifted its holdings in shares of IDEAYA Biosciences by 20.0% in the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after buying an additional 305,698 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of IDEAYA Biosciences by 4.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after buying an additional 50,000 shares during the period. Finally, UBS Group AG lifted its holdings in shares of IDEAYA Biosciences by 2.7% in the 4th quarter. UBS Group AG now owns 1,085,632 shares of the company’s stock worth $37,530,000 after buying an additional 29,055 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on IDYA. Mizuho lowered their target price on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Wall Street Zen upgraded shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. The Goldman Sachs Group increased their price objective on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, April 14th. Citigroup lifted their target price on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $50.69.

IDEAYA Biosciences Stock Down 0.4%

Shares of IDEAYA Biosciences stock opened at $29.54 on Friday. The firm has a market capitalization of $2.60 billion, a P/E ratio of -18.46 and a beta of -0.04. The company has a 50 day moving average price of $31.05 and a 200 day moving average price of $32.82. IDEAYA Biosciences, Inc. has a 52 week low of $18.25 and a 52 week high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the company posted ($0.82) earnings per share. The business’s revenue for the quarter was down 39.4% compared to the same quarter last year. As a group, research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeffrey Stein purchased 50,000 shares of the stock in a transaction on Monday, March 2nd. The stock was bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the transaction, the director owned 54,281 shares in the company, valued at $1,789,101.76. The trade was a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.70% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.